A new West Virginia law is being read as a state-level prescription pathway for psilocybin that gets out ahead of federal scheduling. It is closer to the reverse. SB 906 keeps psilocybin a Schedule I substance under state code and adds a single conditional clause: prescribing, distributing, and marketing crystalline-polymorph psilocybin becomes lawful only if the Food and Drug Administration approves such a drug and the Drug Enforcement Administration reschedules it. The law does not run ahead of federal action. It waits for it, and pre-clears state code to fall in line automatically the moment Washington moves. That structure, and the specific language the statute uses, quietly take a side in how psilocybin access gets built in this country.
What the law actually does
Psilocybin stays Schedule I in West Virginia. The statute layers on an exception that fires only on two federal triggers, FDA approval and DEA rescheduling of a crystalline-polymorph psilocybin drug, after which prescription, distribution, and marketing become lawful in line with the FDA’s recommendations. Until both of those happen, nothing changes. No one can prescribe psilocybin in West Virginia under this law today. It is a trigger law, inert until federal approval, then self-executing. The practical near-term effect is zero, and the reading that it leaps ahead of federal scheduling is backwards: it is explicitly subordinate to it.
Why a law that does nothing yet is still worth reading
Trigger laws are how legislatures place bets cheaply. West Virginia gets to signal support for medical psilocybin at no present cost and with no present access, leaving the hard and contested work to the FDA and the DEA. But the bet it places is specific, and the specificity is the signal. The law aligns the state with one of the two diverging routes to legal psilocybin, and pointedly not the other.
One route is the regulated-access model that Oregon and Colorado built, which operates outside the FDA framework entirely: state-licensed supervised-service centers, trained facilitators, and psilocybin that never requires federal drug approval. The other is the conventional pharmaceutical route, an FDA-approved, DEA-rescheduled psilocybin product prescribed like any other drug. SB 906 is a pure expression of the second model. It does nothing for the supervised-service route and everything, eventually, for the prescription-drug route. It is a state betting that the pharmacy, not the service center, is how psilocybin becomes medicine.
The polymorph language and the Compass intersection
The statute does not simply say psilocybin. It says crystalline polymorph psilocybin, and that phrasing maps directly onto the pharmaceutical model’s intellectual-property architecture. Compass Pathways, furthest advanced with its synthetic crystalline psilocybin COMP360, now in Phase 3 for treatment-resistant depression, has built a layered patent estate in which the crystalline polymorph, its Polymorph A, is a central claim. That claim functions as a barrier to generic competition that persists even after the psilocybin molecule itself is in the public domain, the same polymorph-protection strategy used across small-molecule pharma. So the realistic first product capable of satisfying West Virginia’s trigger, an FDA-approved crystalline-polymorph psilocybin, is a Compass-style pharmaceutical, not a mushroom extract or a compounded preparation.
The statute names no company, and it should not be read as a grant to one. The polymorph framing is generic, and a 2022 patent ruling that interpreted Compass’s claims narrowly left competitors room to manufacture crystalline psilocybin that is not Compass’s specific form. MindMed’s lysergide program is the nearest competitive pressure in the broader category, though on a different molecule. But directionally, the law pre-positions the patented, pharmaceutically manufactured version of psilocybin as the one West Virginia is prepared to allow, and writes that preference into its code using the vocabulary of the patent estate.
The caveats
The near-term impact is nil, and that bears repeating against any headline suggesting the state legalized prescription psilocybin. The entire mechanism is contingent on an FDA approval that has not happened, since COMP360 remains in Phase 3, and the law is inert until it does. The polymorph language is generic statutory drafting rather than a company-specific entitlement. And a single state’s trigger law is a small data point; West Virginia is reported to join only a small group of states building prescription-oriented frameworks, which is a trend in formation, not an established one.
The frame
SB 906 is, for now, a law that does nothing, and its importance is entirely as a marker. It shows a conservative state choosing the FDA-prescription model of psilocybin over the regulated-access model, pre-clearing the pharmaceutical pathway while leaving the supervised-service route untouched, and doing so in language that tracks the IP architecture of the companies, Compass chief among them, building the patented product. The bifurcation of psilocybin access, pharmaceutical prescription on one side and state-regulated service on the other, is one of the defining structural questions of the field, and trigger laws like this one are how states are quietly casting their votes. The claim that West Virginia legalized prescription psilocybin is wrong twice over: it legalized nothing yet, and what it conditionally enabled is not access but alignment, with the federal approval process and with the pharmaceutical model that process favors. The states are beginning to choose sides in how psilocybin will be sold, and the prescription model, the one that runs through the FDA and the patent office, just picked up another quiet vote.